Jurnal Manajemen dan Pelayanan Farmasi, 2020 Zoledronic acid and ibandronic acid are listed in the Indonesian national formulary to prevent skeletal-related events (SRE) in patients diagnosed with bone metastasis in multiple myeloma (MM), with limited evidence to compare their effectiveness.
Nutrisia Aquariushinta Sayuti +3 more
doaj +1 more source
Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models. [PDF]
, 2015 Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy.
Bouvet, Michael +9 more
core +3 more sources
KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models [PDF]
, 2017 BACKGROUND: In non-small cell lung cancer (NSCLC) KRAS-mutant status is a negative prognostic and predictive factor. Nitrogen-containing bisphosphonates inhibit prenylation of small G-proteins (e.g.
Barone +44 more
core +1 more source
Denosumab versus zoledronic acid in elderly patients after hip fracture
Journal of Orthopaedic Surgery, 2022 Background Two injectable anti-osteoporosis medications, denosumab and zoledronic acid, have been widely used to treat patients with severe osteoporosis.
Seung-Ju Kim, Ji Woon Kim, Dong-Woo Lee
doaj +1 more source
Decreased risk of breast cancer associated with oral bisphosphonate therapy [PDF]
, 2012 Preclinical studies and adjuvant trials using bisphosphonates have found them to have an antitumor effect. Although major advances have been made in chemoprevention strategies with selective estrogen receptor modulators and aromatase inhibitors, their ...
Brufsky, A, Mathew, A
core +2 more sources
Activation of BK(Ca) channels in zoledronic acid-induced apoptosis of MDA-MB-231 breast cancer cells. [PDF]
PLoS ONE, 2012 BACKGROUND: Zoledronic acid, one of the most potent nitrogen-containing biphosphonates, has been demonstrated to have direct anti-tumor and anti-metastatic properties in breast cancer in vitro and in vivo.
Yu-Guang Ma +10 more
doaj +1 more source
Cellular and molecular mediators of bone metastatic lesions [PDF]
, 2018 Bone is the preferential site of metastasis for breast and prostate tumor. Cancer cells establish a tight relationship with the host tissue, secreting factors that stimulate or inhibit bone cells, receiving signals generated from the bone remodeling ...
Battafarano, Giulia +3 more
core +6 more sources
Life-threatening hyperkalemia following zoledronic acid infusion for Paget's disease: a case report
Journal of Medical Case Reports, 2011 Introduction Zoledronic acid is a highly effective treatment in Paget's disease for persistent bone pain and prevention of further progression of the disease. The commonest electrolyte abnormality is hypocalcemia. To the best of our knowledge this is the
Naysmith Morag +2 more
doaj +1 more source
Cost-utility of adjuvant zoledronic acid in patients with breast cancer and low estrogen levels [PDF]
, 2015 BACKGROUND: Adjuvant zoledronic acid (za) appears to improve disease-free survival (dfs) in women with early-stage breast cancer and low levels of estrogen (lle) because of induced or natural menopause.
Lamond, Nathan W D +3 more
core +1 more source
Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
Journal of Bone Oncology, 2014 Bone metastases represent common long term complications of patients with breast cancer. Zoledronic acid, an amino-bisphosphonate and mevalonate pathway inhibitor, is an established agent for the treatment of bone metastases.
Maria Wilke +8 more
doaj +1 more source